| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥3321.5B | ¥3596.2B | -7.6% |
| Operating Income | ¥145.0B | ¥95.3B | +52.0% |
| Ordinary Income | ¥303.5B | ¥129.8B | +133.9% |
| Net Income | ¥216.1B | ¥-247.1B | - |
| ROE | 4.9% | -6.0% | - |
UBE Corporation's FY2026 Q3 consolidated results show revenue of 332.2B yen (YoY -7.6%) with operating income of 14.5B yen (+52.0%), ordinary income of 30.3B yen (+133.9%), and net income attributable to owners of 21.1B yen (prior year loss of -19.1B yen). The company achieved a significant turnaround to profitability despite revenue decline, driven by restructuring benefits in the Polymers and Chemicals segment where prior-year impairment charges reduced current depreciation expenses, non-periodic maintenance year effects, and substantial contributions from equity method investments totaling 12.8B yen. The acquisition of Urethane Systems business in April 2025 added 11 consolidated subsidiaries globally, increasing the total from 34 to 45 entities. Operating cash flow of 32.5B yen represents 1.54x net income, indicating solid cash-backed earnings quality, though free cash flow was negative 85.0B yen due to large-scale M&A investments (71.5B yen for subsidiary acquisitions) and capital expenditures (51.1B yen) focused on specialty product capacity expansion. The company maintains full-year guidance of revenue 490.0B yen, operating income 25.0B yen, ordinary income 37.5B yen, and net income 27.5B yen unchanged.
Revenue declined 7.6% YoY to 332.2B yen, primarily driven by reduced sales in the Polymers and Chemicals segment (-9.5%) due to competitive pressures in caprolactam and weak overseas demand for nylon polymers, the Pharmaceutical segment (-42.3%) from lower contract manufacturing volumes, and the Machinery segment (-25.1%) reflecting the prior-year divestiture of the steelmaking business. The High Performance Urethanes segment grew 175.7% from the April 2025 acquisition of Urethane Systems operations encompassing 11 global companies, though this represents only six months of contribution (April-September for December fiscal year-end entities).
Operating income improved 52.0% to 14.5B yen despite revenue decline, demonstrating significant margin expansion. The Polymers and Chemicals segment achieved an 81B yen profit versus prior-year loss of 2.4B yen, primarily from reduced depreciation expenses following prior-year impairment charges on ammonia, caprolactam, and nylon polymer assets, decreased maintenance costs in a non-periodic repair year for the ammonia plant, and lower elastomer raw material costs. This non-recurring benefit from prior-year impairment charges constitutes a significant factor in operating profit improvement.
Ordinary income surged 133.9% to 30.3B yen, substantially outpacing operating income growth. This gap is explained by equity method investment income of 12.8B yen (including 10.5B yen from UBE Mitsubishi Cement) and foreign exchange gains of 3.9B yen, together contributing 16.7B yen or 110% of operating income. This indicates profit composition heavily dependent on non-operating factors.
Net income attributable to owners reached 21.1B yen versus prior-year loss of 19.1B yen, representing a 40.2B yen improvement. The conversion from ordinary income to net income shows a 30% reduction, primarily from corporate and other taxes. No material extraordinary items are disclosed in the current period.
Performance pattern: Revenue down, profit up. The profit improvement is driven by cost structure benefits from prior-year restructuring actions and substantial non-operating income contributions, rather than organic business growth, warranting careful assessment of sustainability.
Specialty Products (core business): Revenue of 44.9B yen (-5.5%) with operating income of 6.7B yen (-5.1%) and margin of 14.9%. This segment represents the company's highest-margin business. Polyimide varnish sales declined due to reduced smartphone production. Separation membranes faced inventory adjustments at some biogas purification customers. Ceramics for automotive applications suffered from slower electric vehicle market growth. Separator products showed volume growth in hybrid vehicle applications. Despite revenue decline, this segment maintained strong profitability and represents a key growth platform with ongoing capacity expansions of 20% for polyimide film, 80% for separation membrane modules (commenced operations November 2025), and 50% for ceramics.
Polymers and Chemicals (largest segment by revenue): Revenue of 184.6B yen (-9.5%) with operating income of 8.1B yen (prior year loss of 2.4B yen) and margin of 4.4%. This turnaround from loss to profit was the primary driver of consolidated operating income improvement. The profit recovery reflects non-recurring benefits from prior-year impairment-related depreciation reductions and maintenance cycle timing rather than underlying business improvement. Nylon polymer sales volume declined on weak overseas demand in food packaging film applications, and caprolactam faced intensified competition. The company is accelerating structural reforms with caprolactam production cessation in Thailand moved forward to March 2026 (originally March 2027) and nylon polymer downsizing to one production line by March 2026.
High Performance Urethanes: Revenue of 31.5B yen (+175.7%) with operating loss of 1.4B yen (prior year profit of 0.1B yen) and margin of -4.4%. The acquisition of Urethane Systems business in April 2025 added substantial revenue but contributed negative operating income due to post-merger integration (PMI) costs and weak high-performance coatings sales. Only six months of results are reflected in Q3 cumulative figures due to December fiscal year-end of acquired entities. This segment represents a strategic investment for future growth with near-term profitability pressure.
Pharmaceutical: Revenue of 14.5B yen (-42.3%) with operating loss of 0.9B yen (prior year profit of 0.9B yen) and margin of -6.1%. Significant revenue and profit deterioration driven by reduced contract manufacturing volumes.
Machinery: Revenue of 46.7B yen (-25.1%) with operating income of 3.9B yen (-21.4%) and margin of 8.3%. Revenue decline primarily reflects the prior-year divestiture of steelmaking business, with additional pressure from weak molding machine product sales and reduced industrial machinery sales.
Other (including Energy): Revenue of 25.5B yen (-13.5%) with operating income of 1.6B yen (+0.2%) and margin of 6.3%. Power generation business experienced lower electricity selling prices following coal price declines, but operating income was maintained through reduced maintenance costs in a non-periodic repair year.
Segment contribution analysis: The Polymers and Chemicals segment delivered the largest absolute profit contribution increase of approximately 10.5B yen, accounting for the entire consolidated operating income improvement. However, this is heavily influenced by one-time depreciation benefits rather than sustainable operational improvements.
Profitability: ROE 4.8% (PY -6.3%), ROA 2.3% (PY -2.9%), Operating Margin 4.4% (PY 2.6%), Net Profit Margin 6.5% (PY -6.9%), EBITDA Margin 10.1%. The company's ROE of 4.8% shows recovery from prior-year losses but remains below the manufacturing industry median of 5.0%.
DuPont Analysis: ROE of 4.8% decomposes into Net Profit Margin 6.3% x Asset Turnover 0.357x x Equity Multiplier 2.10x. The primary driver of ROE improvement is net profit margin recovery from prior-year losses to 6.3% positive. Asset turnover of 0.357x remains significantly below the industry median of 0.58, indicating low capital efficiency and substantial room for improvement in asset utilization.
Cash Quality: Operating CF/Net Income 1.54x indicates healthy cash conversion with earnings well-supported by operating cash generation. OCF/EBITDA 0.97x shows nearly complete conversion of EBITDA to operating cash. However, working capital metrics show concerning trends with Days Sales Outstanding at 111.8 days, Days Inventory Outstanding at 74.9 days, and Cash Conversion Cycle at 87.4 days.
Investment: CapEx/Depreciation 2.70x reflects aggressive investment stance with capital expenditures of 51.1B yen substantially exceeding depreciation of 18.9B yen, indicating growth investment phase. This aligns with disclosed capacity expansion projects in specialty products and the C1 Chemical DMC/EMC plant construction in the United States.
Financial Health: Equity Ratio 47.7% (PY 47.6%), Current Ratio 164.0%, Quick Ratio 128.7%. The equity ratio of 47.7% compares unfavorably to the industry median of 63.8%, indicating higher financial leverage. Debt/EBITDA of 7.92x represents elevated leverage levels warranting monitoring. Interest-bearing debt stands at 265.0B yen.
R&D Intensity: Specific R&D expense data not disclosed in XBRL.
Operating CF: 32.5B yen representing 1.54x net income and 0.97x EBITDA, indicating solid cash earnings quality with profits largely converted to cash. Operating cash flow benefited from inventory reduction of 12.0B yen and accounts receivable reduction of 1.4B yen, partially offset by working capital movements. The OCF/Net Income ratio above 1.0x demonstrates healthy cash generation backing reported earnings.
Investing CF: Negative 117.5B yen primarily consisting of subsidiary stock acquisitions of 71.5B yen for the Urethane Systems business acquisition and property, plant and equipment/intangible asset purchases of 51.1B yen for specialty product capacity expansion projects. This represents a major investment year with strategic M&A and organic growth capital deployment. Tangible fixed asset sales generated 2.8B yen of proceeds.
Financing CF: Positive 15.8B yen with long-term borrowings and bond issuances of 41.4B yen to partially fund investment activities, offset by long-term debt repayments of 14.6B yen and dividend payments of 10.7B yen. The company is utilizing debt financing to support its investment program.
FCF: Negative 85.0B yen (Operating CF 32.5B yen minus CapEx 51.1B yen minus M&A 71.5B yen estimated). The substantial negative free cash flow reflects the extraordinary investment year and is not sustainable long-term without corresponding return generation.
Cash position: Cash and deposits decreased 62.9B yen from 115.9B yen to 53.1B yen, representing a 54.2% decline. The cash/short-term liabilities ratio of 0.67x indicates thin liquidity buffer, though the current ratio of 164.0% suggests adequate near-term solvency through current assets. The cash reduction reflects large-scale deployment for M&A and capital projects.
Cash generation assessment: Needs Monitoring. While operating cash flow generation is adequate relative to earnings, the combination of negative free cash flow, elevated Debt/EBITDA at 7.92x, and reduced cash reserves creates financial flexibility constraints. The sustainability of the investment program depends on successful return realization from deployed capital, particularly the Urethane Systems acquisition and specialty product expansions.
Ordinary vs Net Income: Ordinary income of 30.3B yen converted to net income of 21.1B yen, a 30% reduction primarily attributable to normal corporate and other taxes. No material extraordinary gains or losses are identified in the current period.
Non-Operating Income Composition: Non-operating income contributed 15.8B yen net to ordinary income, representing 109% of operating income and exceeding the 5% materiality threshold substantially. Key components include equity method investment income of 12.8B yen (42% of ordinary income) with 10.5B yen from UBE Mitsubishi Cement Corporation and foreign exchange gains of 3.9B yen (13% of ordinary income). This heavy reliance on equity method income and FX gains for profit generation indicates earnings quality concerns as these items may not be sustainable or controllable.
Recurring vs Non-Recurring Items: The Polymers and Chemicals segment profit improvement of approximately 10.5B yen includes significant non-recurring benefits from reduced depreciation expenses following prior-year impairment charges on ammonia, caprolactam, and nylon polymer assets, and reduced maintenance costs in a non-periodic repair year for the ammonia plant. These factors are explicitly one-time or cyclical rather than sustainable operational improvements. The High Performance Urethanes segment recorded PMI costs that are also non-recurring integration expenses.
Accruals Quality: Operating CF of 32.5B yen represents 1.54x net income, indicating low accruals and high-quality earnings from a cash realization perspective. OCF exceeding net income is a positive signal for earnings quality. However, the substantial increase in goodwill (42.2B yen) and intangible assets (57.0B yen) from the Urethane Systems acquisition introduces future amortization burden and potential impairment risk.
Overall Assessment: Earnings quality is mixed. Cash conversion is strong, but profit composition shows heavy dependence on non-operating items (equity method income 42% of ordinary income, FX gains 13%) and one-time benefits in the Polymers and Chemicals segment. The sustainability of reported earnings improvement requires careful monitoring of underlying operational performance excluding these factors.
Full-year guidance unchanged at revenue 490.0B yen, operating income 25.0B yen, ordinary income 37.5B yen, and net income 27.5B yen.
Progress rate vs. full-year guidance at Q3 (9 months): Revenue 67.8% (332.2B/490.0B), Operating Income 58.0% (14.5B/25.0B), Ordinary Income 80.9% (30.3B/37.5B), Net Income 76.6% (21.1B/27.5B). Standard progress would be 75% at Q3.
Revenue progress of 67.8% trails the 75% standard by 7.2 percentage points, suggesting Q4 revenue acceleration is required to achieve guidance or potential downside risk exists. Operating income progress of 58.0% significantly trails by 17.0 percentage points, indicating substantial Q4 profit generation is required. Conversely, ordinary income progress of 80.9% and net income progress of 76.6% exceed standard rates, suggesting these targets may be achievable given strong Q1-Q3 non-operating income contributions.
The divergence between operating income progress (58.0%) and ordinary income progress (80.9%) reflects the outsized contribution of equity method income and other non-operating items in the first nine months. If equity method income and non-operating items normalize in Q4, achieving the operating income target while ordinary income remains on track could prove challenging.
Segment-level guidance implications: The Polymers and Chemicals segment has benefited from non-recurring depreciation and maintenance timing effects that may not repeat in Q4. The High Performance Urethanes segment shows Q3 cumulative losses despite revenue addition, indicating integration challenges. Revenue growth acceleration in Q4 would need to come from recovery in Specialty Products, stabilization in High Performance Urethanes, or Machinery segment contribution.
Management has not revised guidance, suggesting confidence in Q4 performance, though revenue and operating income progress rates indicate execution risk remains for full-year achievement.
Dividend policy: Interim dividend of 55 yen per share and year-end dividend of 55 yen per share for total annual dividend of 110 yen per share, maintained at prior year level. The company targets a dividend on equity (DOE) of 2.5% or higher and aims for progressive dividends in the latter three years of the mid-term management plan.
Payout ratio: Calculated payout ratio is 55.4% based on full-year net income guidance of 27.5B yen and annual dividend of 110 yen per share (approximately 15.2B yen total dividends estimated). This payout ratio is within sustainable range below 60% from an earnings perspective.
Dividend coverage: Operating cash flow of 32.5B yen covers estimated dividends of 10.7B yen paid in the nine-month period at 3.0x, indicating adequate coverage from operating cash generation. However, free cash flow of negative 85.0B yen indicates dividends are not covered by FCF and are being funded through operating CF while investment activities are financed by debt. FCF coverage of dividends is negative 7.96x.
Share buybacks: No share buyback activity is disclosed in the current period. Total return ratio equals the dividend payout ratio of 55.4%.
Sustainability assessment: Dividends appear sustainable in the near term based on operating cash flow generation and the company's stated DOE policy and progressive dividend intention. However, the combination of negative free cash flow, elevated leverage (Debt/EBITDA 7.92x), and declining cash reserves (54.2% reduction to 53.1B yen) creates medium-term sustainability questions if the large-scale investment program does not generate expected returns. The company would need to either reduce investment intensity, improve operating cash flow generation, or potentially constrain dividend growth to restore financial flexibility. Current dividend is supportable but warrants monitoring given the capital-intensive investment phase and leverage levels.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 4.8% vs. Industry Median 5.0% (manufacturing sector, Q3 2025, N=98 companies). UBE's ROE slightly trails the industry median despite improvement from prior-year losses, indicating room for profitability enhancement to reach peer levels. Operating Margin 4.4% vs. Industry Median 8.3%, showing UBE operates at approximately half the median manufacturing sector operating margin, reflecting the commodity-heavy business mix in Polymers and Chemicals. Net Profit Margin 6.5% matches Industry Median 6.3%, indicating bottom-line profitability has recovered to peer levels after non-operating income contributions.
Efficiency: Asset Turnover 0.357x vs. Industry Median 0.58x, indicating UBE's asset utilization is significantly below peer levels at 62% of median, highlighting substantial inefficiency in capital deployment and opportunity for improvement through portfolio optimization and asset productivity enhancement. Operating Working Capital Turnover 87.4 days vs. Industry Median 108.1 days, showing UBE manages working capital more efficiently than peers on a relative basis.
Financial Health: Equity Ratio 47.7% vs. Industry Median 63.8%, indicating UBE maintains higher financial leverage than industry peers with equity representing only 75% of the median level, warranting monitoring given the elevated Debt/EBITDA ratio. Current Ratio 164.0% vs. Industry Median 284%, showing UBE's short-term liquidity position is below peer levels at 58% of median, though still within acceptable range above 150%.
Growth: Revenue Growth -7.6% vs. Industry Median +2.7%, placing UBE in the bottom quartile for top-line growth as peers generally achieved revenue expansion while UBE experienced contraction from commodity business headwinds and business portfolio transitions.
Investment Intensity: CapEx/Depreciation 2.70x vs. Industry Median 1.44x, indicating UBE is investing at nearly double the industry median rate relative to depreciation, reflecting the aggressive capacity expansion program in specialty products and major M&A activity in the current period.
Returns: ROIC 5.0% vs. Industry Median 5.0% (estimated based on proprietary data), showing UBE's return on invested capital aligns with peer median levels.
Industry: Manufacturing sector (N=98 companies), Comparison: FY2025 Q3 period, Source: Proprietary analysis
Financial leverage and liquidity constraints: Debt/EBITDA ratio of 7.92x substantially exceeds healthy levels (typically below 3-4x), combined with negative free cash flow of 85.0B yen and cash reserves declined 54.2% to 53.1B yen. The company's elevated leverage limits financial flexibility and creates refinancing risk if investment returns disappoint. Current cash/short-term liabilities ratio of 0.67x provides limited buffer for unexpected cash needs. Interest coverage and debt service capacity warrant close monitoring given the leverage profile. Quantified impact: Every 1 percentage point increase in interest rates would increase annual interest expense by approximately 2.7B yen on 265.0B yen debt, consuming 18% of current operating income.
M&A integration and impairment risk: Goodwill increased to 42.2B yen and intangible assets to 57.0B yen from the Urethane Systems acquisition of 11 global entities. The High Performance Urethanes segment generated operating losses of 1.4B yen in the first six months post-acquisition despite revenue contribution of 31.5B yen, indicating challenging integration and profitability pressures. If the acquisition fails to achieve planned synergies or market conditions deteriorate, impairment charges similar to the prior-year Polymers and Chemicals impairments could materialize, potentially exceeding 40-50B yen based on the scale of acquired assets. PMI costs and high-performance coatings weakness suggest near-term profitability challenges that could extend the payback period.
Earnings sustainability and non-operating income dependence: Profit improvement heavily relies on non-recurring factors including (a) reduced depreciation from prior-year impairments contributing approximately 10B yen benefit in Polymers and Chemicals, (b) non-periodic maintenance year timing benefits, (c) equity method income of 12.8B yen representing 42% of ordinary income and 88% of operating income, and (d) foreign exchange gains of 3.9B yen. If equity method income normalizes, FX rates reverse, or one-time depreciation benefits do not recur, operating income could decline substantially. The company's guidance implies Q4 operating income must reach approximately 10.5B yen (42% of full-year target) compared to Q1-Q3 average of 4.8B yen per quarter, representing a 118% increase, which appears challenging without non-recurring tailwinds continuing. The structural competitiveness issues in nylon polymers and caprolactam persist with accelerated exit timelines, indicating management acknowledges these businesses cannot achieve sustainable profitability.
Profitability turnaround achieved but sustainability uncertain: The company demonstrated significant profit recovery with operating income improving 52.0% to 14.5B yen and net income reaching 21.1B yen from prior-year losses of 19.1B yen. However, this improvement substantially depends on non-recurring factors including reduced depreciation expenses from prior-year impairments (approximately 10B yen benefit in Polymers and Chemicals), maintenance cycle timing, and non-operating income contributions of equity method income (12.8B yen) and FX gains (3.9B yen) that together exceed operating income. The underlying operational performance excluding these factors shows more modest improvement, with the core Specialty Products segment declining 5.1% in operating profit and newly acquired High Performance Urethanes generating losses. Revenue declined 7.6% with no segment achieving organic growth excluding acquisitions, indicating limited underlying business momentum. Earnings quality analysis reveals strong cash conversion (OCF/Net Income 1.54x) but heavy composition from non-operating sources, warranting careful monitoring of future earnings power as non-recurring benefits diminish.
Aggressive capital deployment with near-term financial pressure: The company executed a major strategic transformation through the 71.5B yen Urethane Systems acquisition and 51.1B yen capital expenditures for specialty product capacity expansions, resulting in negative free cash flow of 85.0B yen and cash reserve depletion of 54.2% to 53.1B yen. Financial leverage increased to Debt/EBITDA of 7.92x, substantially above healthy levels and industry norms. While the investment strategy targets portfolio shift from low-margin commodity chemicals to high-margin specialty products, near-term profitability from these investments remains uncertain as evidenced by High Performance Urethanes segment losses and ongoing PMI costs. The specialty capacity expansions (separation membrane +80%, polyimide +20%, ceramics +50%, separator +30%) represent significant growth potential but require successful commercialization and market acceptance to generate returns justifying the capital intensity. The company maintains current ratio of 164.0% providing adequate liquidity, but thin cash reserves (cash/short-term liabilities 0.67x) and negative FCF create financial flexibility constraints that could limit strategic options if investment returns disappoint or market conditions deteriorate.
Portfolio restructuring progressing with execution risk: Management is accelerating the exit from unprofitable commodity chemical operations with caprolactam Thailand production cessation moved forward to March 2026, nylon polymer downsizing to one line by March 2026, and planned exits from Japan caprolactam (March 2027), nylon polymer (March 2027), and ammonia (March 2028). These actions address the structural issues that led to prior-year impairments and operating losses in Polymers and Chemicals. However, the restructuring timeline extends through 2028, creating a multi-year transition period where the company operates subscale commodity assets while investing heavily in specialty products that are still ramping production and sales. Full-year guidance implies substantial Q4 acceleration is required with operating income needing to reach 10.5B yen in Q4 (versus Q1-Q3 average of 4.8B yen) to achieve the 25.0B yen target, representing 118% sequential increase that appears challenging. The success of the transformation depends on (1) specialty product capacity expansions achieving targeted margins and volumes, (2) High Performance Urethanes achieving breakeven and profitability post-integration, (3) successful execution of commodity business exits without additional restructuring charges, and (4) UBE Mitsubishi Cement continuing stable equity method income contributions. Asset turnover of 0.357x at 62% of industry median highlights substantial room for efficiency improvement that the portfolio restructuring aims to address.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
Presentation materials for UBE Corporation’s Q3 FY2026 (fiscal year ending March 2026) results. The number of consolidated subsidiaries increased from 34 to 45, largely due to the acquisition of 11 global companies in the Urethane Systems business. Net sales declined to 332.2 billion yen (down 7.6% year on year), but operating profit rose to 14.5 billion yen (+52.0%), ordinary profit to 30.3 billion yen (+133.9%), and profit attributable to owners of parent to 21.1 billion yen (a turnaround from △19.1 billion yen in the prior year), delivering a significant earnings improvement. In the Resins and Chemicals segment, lower depreciation following impairment losses recognized in the previous fiscal year for ammonia, caprolactam, and nylon polymer, reduced repair expenses due to a non-scheduled maintenance year at the ammonia plant, and lower feedstock prices for elastomers bolstered profits. The High-performance Urethane segment increased sales to 31.5 billion yen due to the business acquisition in April 2025, but posted an operating loss of △1.4 billion yen on PMI expenses and weakness in high-performance coatings. The Pharmaceuticals segment saw a decline in sales and profit due to lower contract product sales. The Machinery segment recorded lower sales and profit due to the impact of the prior-year transfer of the steel business. Equity in earnings of affiliates from the UBE-Mitsubishi Cement Group was 10.5 billion yen, down △2.4 billion yen year on year.
Acquired the Urethane Systems business (11 companies globally) in April 2025, substantially increasing the number of consolidated subsidiaries from 34 to 45. Resins and Chemicals segment: operating profit of 8.1 billion yen (a turnaround from △2.4 billion yen in the prior year) driven by reduced depreciation from prior-year impairment of ammonia, caprolactam, and nylon polymer, and lower repair costs due to a non-scheduled maintenance year. High-performance Urethane segment: sales increased to 31.5 billion yen, but posted an operating loss of △1.4 billion yen due to PMI expenses and sluggish high-performance coatings. Ordinary profit was 30.3 billion yen (+133.9%), supported significantly by 12.8 billion yen in equity-method gains (of which UBE-Mitsubishi Cement contributed 10.5 billion yen) and 3.9 billion yen in foreign exchange gains. Profit attributable to owners of parent was 21.1 billion yen, an improvement of 40.2 billion yen from the prior year’s △19.1 billion yen.
Full-year guidance is maintained at net sales of 490.0 billion yen, operating profit of 25.0 billion yen, ordinary profit of 37.5 billion yen, and net income of 27.5 billion yen. Q3 progress rates are 67.8% for net sales, 58.0% for operating profit, 80.9% for ordinary profit, and 76.6% for net profit. Segment full-year forecasts: Specialty Products sales 69.0 billion yen and operating profit 12.5 billion yen; High-performance Urethane sales 50.5 billion yen and operating profit 1.0 billion yen; Resins and Chemicals sales 257.0 billion yen and operating profit 9.5 billion yen; Machinery sales 74.0 billion yen and operating profit 6.5 billion yen.
To realize management that is conscious of capital costs and share price, improving ROE and lowering the cost of equity will underpin PBR enhancement. Promote capacity expansion and M&A utilization in specialty businesses, and drive new business creation. In Resins and Chemicals, accelerate structural reforms for ammonia, caprolactam, and nylon polymer (caprolactam production to cease in March 2026; nylon polymer to be reduced to one line in March 2026). Shareholder returns: maintain DOE of 2.5% or higher and target a progressive dividend in the latter three years of the mid-term management plan.
Expansion of specialty businesses: Polyimide film manufacturing capacity (+20%, commercial operation after certification obtained); hollow-fiber separation membrane and module manufacturing capacity (+80%, commercial operation commenced in November 2025); ceramics manufacturing capacity (+50%, plant under construction); separator manufacturing capacity (+30%, plant under construction); C1 chemicals DMC/EMC plants in the U.S. (100,000 t/40,000 t, plants under construction). High-performance Urethane business: acquired the Urethane Systems business in April 2025 and focusing on the U.S. business; while recognizing integration (PMI) costs, building a foundation for medium- to long-term growth. Restructuring in Resins and Chemicals: in Thailand, caprolactam production to cease in March 2026 (moved up from March 2027) and nylon polymer to be reduced to one line in March 2026 (moved up from March 2027). In Japan, caprolactam to cease in March 2027, nylon polymer to cease in March 2027, and ammonia to cease in March 2028. Promotion of sustainability management: on track to achieve a 50% reduction in GHG emissions by FY2030 versus FY2013. Set FY2030 targets of 25.0% for the ratio of female employees, 10.0% for the ratio of female managers, an increased ratio of mid-career hires, and 300,000 yen per capita investment in human capital. Improving capital efficiency: to achieve the ROE target, drive profitability improvement (ROIC enhancement) and transition to a business portfolio less susceptible to market fluctuations.
Resins and Chemicals segment: declining overseas demand for nylon polymer (e.g., food packaging film applications) and intensifying competition leading to lower sales volumes and price declines. High-performance Urethane segment: continued recognition of integration (PMI) expenses and sluggish sales in the high-performance coatings business. Pharmaceuticals segment: decrease in sales volumes of contract products. Machinery segment: weak product sales in the molding machine business and lower product sales in the industrial machinery business. Foreign exchange and raw material price fluctuations: although resource prices have declined—FX rate at 148.7 yen/USD (prior year 152.6 yen), naphtha CIF 611 USD/t (prior year 703 USD), domestic naphtha 64,800 yen/KL (prior year 76,400 yen), Australian coal CIF 137.8 USD/t (prior year 161.0 USD)—there is risk of future volatility.